About Motif (NASDAQ:MTFB)
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus. Motif Bio plc was incorporated in 2014 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MTFB
CUSIPN/A
Phone212-210-6248
Debt
Debt-to-Equity Ratio-1.58%
Current Ratio0.96%
Quick Ratio0.96%
Price-To-Earnings
Trailing P/E Ratio-52.11
Forward P/E Ratio-3.64
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-198.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees6
Outstanding Shares196,210,000
Motif (NASDAQ:MTFB) Frequently Asked Questions
What is Motif's stock symbol?
Motif trades on the NASDAQ under the ticker symbol "MTFB."
When is Motif's next earnings date?
What price target have analysts set for MTFB?
5 Wall Street analysts have issued 1 year price objectives for Motif's shares. Their predictions range from $7.00 to $32.00. On average, they expect Motif's share price to reach $19.50 in the next twelve months. View Analyst Ratings for Motif.
What are Wall Street analysts saying about Motif stock?
Here are some recent quotes from research analysts about Motif stock:
- 1. HC Wainwright analysts commented, "Approaches; ECCMID Presentations; Reiterate Buy Stock Data 04/18/2018 Price $10.95 Exchange NASDAQ Price Target $32.00 52-Week High $13.75 52-Week Low $6.84 Enterprise Value (M) $122.3 Market Cap (M) $145 Public Market Float (M) 3.4 Shares Outstanding (M) 13.2 3 Month Avg Volume 2,389 Short Interest (M) 0.00 Balance Sheet Metrics Cash (M) $22.7 Total Debt (M) $0.0 Total Cash/Share $1.72 Book Value/Share $(0.68) EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (1.21) (1.71)A (0.82) 2Q (1.40) (1.19)A (0.76) 3Q NA NA (0.72) 4Q NA NA (0.72) FY (6.92) (4.01) (3.01) Company reports semi-annually; select historical quarterly financial data available from prospectuses. 14 12 10 8 6 APR-17 AUG-17 DEC-17 APR-18 0.12 0.1 0.08 0.06 0.04 0.02 0 Vol. (mil) Price New Drug Application submission completion this quarter." (4/19/2018)
- 2. WBB Securities analysts commented, "We believe there is a critical need for novel antibiotics. Based on the clinical data provided through Phase 3 studies REVIVE-1 and REVIVE-2, iclaprim has a high probability of obtaining FDA approval. However, success for MTFB is not just manifest through clinical proof, but also through negotiating the vagaries of reimbursement, gaining clinician acceptance, hospital inclusion and inclusion in the overall patient care paradigm. Additionally, we remain concerned about the resourcing path regarding the future of iclaprim. We are therefore initiating our coverage of MTFB with a Sell rating and a 12- month price target of $7.00." (12/29/2017)
Who are some of Motif's key competitors?
Some companies that are related to Motif include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).
Who are Motif's key executives?
Motif's management team includes the folowing people:
- Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
- Mr. Jonathan E. Gold, Interim CFO, Strategic Financial Consultant & Non-Exec. Director (Age 45)
- Mr. Robert Joseph Bertoldi, Exec. Director (Age 64)
- Dr. David B. Huang M.D., Ph.D., MBA, J.D., Chief Medical Officer (Age 43)
- Mr. Robert Dickey IV, Advisor (Age 62)
When did Motif IPO?
(MTFB) raised $17 million in an initial public offering on Friday, November 18th 2016. The company issued 2,400,000 shares at $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.
Has Motif been receiving favorable news coverage?
News coverage about MTFB stock has been trending somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Motif earned a daily sentiment score of 0.11 on Accern's scale. They also gave media headlines about the company an impact score of 45.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Motif?
Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Motif's stock price today?
One share of MTFB stock can currently be purchased for approximately $9.90.
How big of a company is Motif?
Motif has a market capitalization of $2.15 billion. The company earns $-44,810,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Motif employs 6 workers across the globe.
How can I contact Motif?
Motif's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]
MarketBeat Community Rating for Motif (MTFB)
MarketBeat's community ratings are surveys of what our community members think about Motif and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Motif (NASDAQ:MTFB) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Motif in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 96.97%. The high price target for MTFB is $32.00 and the low price target for MTFB is $7.00. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Buy | Buy | Buy |
| Consensus Rating Score: | 2.40 | 2.50 | 2.50 | 3.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $19.50 | $21.3333 | $21.3333 | $28.50 |
| Price Target Upside: | 96.97% upside | 107.12% upside | 107.12% upside | 160.65% upside |
Motif (NASDAQ:MTFB) Consensus Price Target History
Motif (NASDAQ:MTFB) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Motif (NASDAQ:MTFB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Motif (NASDAQ MTFB) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 0.56%
Motif (NASDAQ MTFB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Motif (NASDAQ MTFB) News Headlines
| Source: |
|
Motif (NASDAQ:MTFB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Motif (NASDAQ:MTFB) Income Statement, Balance Sheet and Cash Flow Statement
Motif (NASDAQ MTFB) Stock Chart for Thursday, April, 26, 2018
Loading chart…
